ClinicalTrials.gg
RecruitingNCT05739591ETERNITYUpdated Sep 15, 2026

Long-term Safety and Efficacy of GBG Study Participants

An observational study in Breast Cancer, sponsored by GBG Forschungs GmbH. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by GBG Forschungs GmbH · Observational

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.

Planned enrollment
32nd of 97
400 · median 200
Started
2022
with 44 others
Observational
97 of 905
27 open now
Primary completion
2030-05
later than 260 of 284 live
Registered
712th of 905
by date

Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 32nd largest by planned enrollment of the 97 observational ones that give a count, is one of 45 that started in 2022, is one of 97 observational ones, reaches primary completion later than 260 of the 284 other live ones, and was the 712th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

159 more — sign in →

All 164 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.

Read the detailed description

This is a prospective and retrospective, international, multicenter, non-interventional, observational study for collection of long-term safety and efficacy parameters of former GBG study participants of prospective clinical trials on early breast cancer.

Patients with prospective data collection will be informed about the registry by the treating physician at the study site. After written informed consent (which may already be included in the main and/or biomaterial informed consent form of the respective clinical study) for data and biomaterial collection, the registration form will be filled out completely within the GBG electronic data capture system (MEDCODES®). Inclusion and registration can take place after informed consent of the patient. However, documentation of follow-up should start after the regular end of study or with the start of the follow-up period, as defined in the respective study protocol.

A correlation of the follow-up registry database with the respective study databases is possible via the patient identification number of the participant. Consequently, the long-term effects of the study therapy can be calculated per therapy group, and the effectiveness can be correlated with possible late-onset toxicities.

Post-study long-term outcome follow-up will be assessed according to local/national guidelines for standard follow-up examinations and post-treatment surveillance. Data should be documented at least once a year in the registry.

Relapse and safety assessment will be performed, and survival status will be collected in all registered patients. Here, the investigator may conduct evaluations or assessments within regular follow-up visits. However, telephone contact or contact in writing with the patient or treating physician or relatives in case of death is also acceptable. Imaging tests (e.g., mammography and/or staging workup) are recommended according to local/national guidelines for follow-up and in case of symptoms suspicious for locoregional or distant relapse.

Information to be collected include:

  • Date and site of first non-invasive local recurrence, first invasive local recurrence, first contralateral breast recurrence, first regional recurrence, first distant recurrence
  • Date and diagnosis of secondary malignancies
  • Date and cause of deaths
  • Pregnancies after study participation and their respective outcome
  • Anti-hormonal therapies in HR+ breast cancer patients
  • Further anti-cancer treatments after study participation
  • Long-term adverse drug reactions of the respective study treatments

In case of disease recurrence, it is recommended to confirm diagnosis by histological examination. If performed, an FFPE tumor tissue block from the metastatic lesion should be provided to GBG.

It is allowed and recommended to register patients in parallel in the GBG self-reporting registry (available only in German) that will allow follow-up and long-term efficacy evaluations beyond the end of the respective study by the patients themselves.

STATISTICS

This is an observational study for collection of long-term safety and efficacy parameters of former GBG study participants. As long-term outcomes and late-onset toxicities are also secondary objectives in all prospective clinical studies of the GBG, statistical methods will adhere as much as possible to methods described in the respective clinical trial protocols.

For the analysis, data from the corresponding clinical trials (e.g., baseline characteristics, short-time efficacy, and toxicity parameters, already collected follow-up data, etc.) will be merged with the registry data.

DATA HANDLING, MANAGEMENT AND QUALITY ASSURANCE

The GBG EDC system MEDCODES® will be maintained by GBG Forschungs GmbH for all study sites.

Data management, which comprises CRF design, database and application hosting, data entry, and data validation, will be performed by GBG Forschungs GmbH for all study sites. GBG Forschungs GmbH will provide the investigator site with the web base EDC system MEDCODES® that is validated and conforms to 21 CFR Part 11 requirements. Investigator site staff will not be given access to MEDCODES® until they have been trained on the EDC system.

Visual and computerized methods of data validation are applied in order to ensure accurate, consistent, and reliable data for the subsequent analyses.

All communication between MedCODES® and the clients is securely encrypted (Secure HTTP).

In order to protect patient confidentiality, each participating patient is assigned a unique GBG patient identification number. Instead of the true patient identity, the pseudonym is used in all communication between the trial site and the GBG Forschungs GmbH. A correlation of the follow-up registry database with the respective study databases is possible via the patient identification number of the participant.

Every user is provided with a unique username and a unique password. Every user is assigned to a user group which represents their role in the CRF workflow. Access control is based on user name, group. Therefore, users can only access those datasets necessary for them to fulfill their role in the CRF workflow ("need to know basis").

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Registry
  • Breast cancer, early
  • Safety
  • Efficacy
  • Long-term follow-up
  • Long-term survival
  • German Breast Group
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who participated and received treatment as part of a GBG clinical trial for early breast cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation and treatment in a GBG clinical trial for early breast cancer.
  • Prospective registration: Written according to local regulatory requirements prior to data and biomaterial collection.

Exclusion criteria

Exclusion criteria:

  • Participation and treatment in a non-GBG clinical trial for early breast cancer.
  • Patients with advanced or breast cancer who have participated and received treatment in a GBG clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    Time period between randomization and first event (ipsi- or contralateral (non-) in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))

    Time frame: 10 years

  2. Invasive disease-free survival (iDFS)

    Time period between randomization and first event (ipsi- or contralateral invasive in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))

    Time frame: 10 years

  3. Distant disease-free survival (DDFS)

    Time period between randomization and diagnosis of any distant recurrence of disease, any second primary invasive cancer (non-breast) or death due to any cause, whichever occurs first

    Time frame: 10 years

  4. Locoregional recurrence-free survival (LRRFS)

    Time period between randomization and diagnosis of any loco-regional (ipsilateral breast (invasive or DCIS), local/regional lymph nodes) recurrence of disease, any invasive contralateral breast cancer or death due to any cause, whichever occurs first

    Time frame: 10 years

  5. Overall survival (OS)

    Time period between randomization and death of any cause

    Time frame: 10 years

  6. Other primary outcome measures

    Other study-specific long-term survival endpoints may be defined in the respective study protocol or statistical analysis plan (SAP)

    Time frame: 10 years

Secondary outcomes

  1. Long-term toxicity

    Frequency and severity of long-term toxicity associated with study treatment are graded by the current NCI Common Terminology Criteria for Adverse Events version (NCI-CTCAE) or according to the respective study protocol or statistical analysis plan (SAP)

    Time frame: 10 years

  2. Anti-cancer therapies

    Anti-cancer therapies including anti-hormonal therapy in hormone receptor positive (HR+) breast cancer after study participation are analyzed descriptively

    Time frame: 10 years

  3. Pregnancies

    Pregnancies after study participation and their outcome are analyzed descriptively.

    Time frame: 10 years

  4. Impact of study treatment on Quality of Life (QoL)

    In this registry, two questions on content on quality of life and degree of bother by side-effects are used

    Time frame: 10 years

Other outcomes

  1. Explorative translational research endpoints

    Correlation of explorative biomarkers with survival and toxicity endpoints. Details are defined in the corresponding SAP

    Time frame: 10 years

07

Study locations

23 of 23 sites recruiting
  • Universitätsklinikum Innsbruck, Klinische Abteilung f. Gynäkologie und Geburt
    Innsbruck, Triol 6020, Austria
    Recruiting
  • Klinikum Wels-Grieskirchen GmbH
    Wels, Upper Austria 4600, Austria
    Recruiting
  • MedUni Graz - Med. Universitätsklinik, Klinische Abteilung für Onkologie
    Graz, 8036, Austria
    Recruiting
  • MedUni Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe
    Graz, 8036, Austria
    Recruiting
  • Ordensklinikum Linz GmbH - BHS
    Linz, 4010, Austria
    Recruiting
  • LKH Salzburg - PMU
    Salzburg, 5020, Austria
    Recruiting
  • Medical University of Vienna, Brustambulanz AKH Wien
    Vienna, 1090, Austria
    Recruiting
  • Klinik Hietzing Wien
    Vienna, 1130, Austria
    Recruiting
  • Hospital Reina Sofia, Servicio Oncología Planta sotano
    Córdoba, Andalusia 14004, Spain
    Recruiting
  • Hospital Universitario Basurto, Servicio de Oncología médica
    Bilbao, Basque Country 48013, Spain
    Recruiting
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Canary Islands 38320, Spain
    Recruiting
  • Hospital Germans Trias i Pujol
    Badalona, Catalonia 8916, Spain
    Recruiting
  • Hospital Universitari Vall d´Hebron, Servicio de Oncologia Medica
    Barcelona, Catalonia 8035, Spain
    Recruiting
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Catalonia 8036, Spain
    Recruiting
  • H. Santa Creu I Sant Pau
    Barcelona, Catalonia 8041, Spain
    Recruiting
  • Fundació IRB Lleida, Oncología, Unidad de ensayos clínicos
    Lleida, Catalonia 25198, Spain
    Recruiting
  • Hospital Parc Tauli
    Sabadell, Catalonia 8208, Spain
    Recruiting
  • Hospital San Pedro de Alcantara
    Cáceres, Extremadura 10003, Spain
    Recruiting
  • Hospital Universitario Ramon y Cajal, Servicio de Oncología Médica/ Oficina de Ensayos Clínicos
    Madrid, Madrid 28034, Spain
    Recruiting
  • Hospital Universitario Clínico San Carlos, Servicio de Oncología Médica
    Madrid, Madrid 28040, Spain
    Recruiting
  • Fundación Instituto Valenciano de Oncología (IVO)
    Valencia, Valencia 46009, Spain
    Recruiting
  • Hospital Universitario Infanta Cristina, Centro de Investigacíon Clinica e Área de Sal
    Badajoz, 6007, Spain
    Recruiting
  • Hospital Universitario Virgen der Rocio
    Seville, 41013, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for May 2030, 91 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 91 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2023
First posted
Feb 22, 2023
StartActual
Oct 12, 2022
Primary completionEst.
May 19, 2030
CompletionEst.
May 19, 2030
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05739591
Lead sponsor
GBG Forschungs GmbH
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Oct 12, 2022
Primary completion
May 19, 2030 (estimated)
Completion
May 19, 2030 (estimated)
Last update
Sep 15, 2026

Study contacts

Thomas Ballhausen, Dr.
Contact
eternity@gbg.de
0049610274800
Sibylle Loibl, Prof. Dr.
study chair · GBG Forschungs GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion